CAMBRIDGE, Mass., Nov. 15, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that preliminary data from the Phase 1 clinical trials evaluating BLU-285 for the treatment of advanced GIST and BLU-554 for the treatment of advanced HCC will be presented at the 28 th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Munich, Germany, November 29 - December 2, 2016.
The accepted abstracts are listed below. Preliminary data from the Phase 1 clinical trial evaluating BLU-285 for the treatment of unresectable PDGFRa-driven GIST and treatment-resistant KIT-driven GIST will be reported in a late-breaking oral presentation. As a result, the abstract and data will remain embargoed until December 1, 2016 at 7:00 a.m. CET ( 1:00 a.m. ET). The abstract from the Phase 1 clinical trial for BLU-554 for the treatment of advanced HCC is now available online on the conference website at: http://www.ecco-org.eu/Events/ENA2016. Late-Breaking Oral Presentation:Date & Time: Thursday, December 1, 2016 at 4:00 p.m. CET ( 10:00 a.m. ET) Session Title: Proffered Paper Session Abstract Number: 6LBA Presentation Title: Preliminary Safety and Activity in a First-in-Human Phase 1 Study of BLU-285, a Potent, Highly-Selective Inhibitor of KIT and PDGFRa Activation Loop Mutants in Advanced Gastrointestinal Stromal Tumor (GIST) Location: ICM - International Congress Center Munich, Room 14